“Greater recognition of toxicity risks of HPAPIs and continued growth of oncology sector are driving drug industry demand for safe manufacturing capacity says” writes Gareth MacDonald of in-Pharma Technologist, talking about the rationale behind SAFC’s recent $30m expansion of its Verona, Wisconsin HPAPI facility.
Gareth was invited to enjoy an exclusive look behind the scenes at the Verona plant’s capabilities and spoke about the market with operations director David Bormett, who also gave an insight into the containment technologies used at the plant, as well as the trends and growth that SAFC is seeing is the field of highly potent compounds, which offer greater efficacy in smaller doses in numerous areas of medical treatment, particular in the development drugs that target cancers.
Forget MTV Cribs… The really fascinating stuff is happening here…
